You Don't Need to Fix Everything Before Deploying AI in Quality — Here's Why

In our work helping medical device companies prepare for FDA inspections, close 483 observations, and build defensible quality systems, we hear a version of the same story constantly:

"We know we need to modernize our quality operations. We're working on it. We just need to get our systems integrated first — then we can think about AI."

We understand why quality leaders think this way. The regulatory environment is unforgiving. The pressure to maintain compliance while simultaneously transforming digital infrastructure is real. And the volume of industry advice pointing toward "fix everything first" makes it easy to conclude that AI deployment has to wait until the digital foundation is solid.

New survey data from the industry puts numbers to what we've been seeing on the ground. A recent survey of 300 life sciences professionals in quality and manufacturing functions found that between 55% and 64% of organizations are operating in a hybrid "partly manual, partly digital" state for their most critical processes. More striking: zero processes across all surveyed organizations have reached a fully intelligent operational state.

The survey frames this as a connectivity crisis — and it is. Nearly 60% of respondents said integrated systems are essential infrastructure before deploying AI. Nearly 50% of technology time is spent on activities that should have been solved years ago. The dominant prescription: a three-to-five-year infrastructure transformation journey before AI deployment is viable.

In our experience advising regulated companies, that prescription leaves organization

The Cost of Paralysis by Analysis

Here's the tension we observe with clients in the middle of digital transformation programs: while the infrastructure work proceeds, quality risk doesn't pause.

CAPAs accumulate. Audit observations go untracked across product lines. Complaint signals that might indicate a systemic issue sit in one system while the related production records sit in another. The professionals who know where the risk lives are the same ones manually extracting, reconciling, and reporting data — leaving less time for the judgment-intensive work that actually reduces risk.

The "fix everything first" mindset assumes that AI deployment is a reward for completing your digital transformation. In reality, for quality and audit operations specifically, it can be a significant accelerant of the transformation — if the right architecture is used.

The four obstacles the survey identifies — compliance complexity, data visibility gaps, system fragmentation, and operational inefficiencies — are precisely the conditions where audit intelligence generates the most value. Not after those conditions are solved. During them.

The Intelligence Layer vs. the Infrastructure Question

MB&A distinguishes between two different types of AI deployment decisions, and we think this distinction matters enormously for how quality leaders allocate their transformation budgets and timelines.

Infrastructure AI — the type that requires a fully unified, connected digital foundation — is genuinely a multi-year journey. If you're looking to replace your QMS, unify your manufacturing execution system, and build a connected data architecture from the ground up, plan accordingly. That work is real, it's complex, and it requires the phased approach the survey describes.

Audit intelligence — specifically, purpose-built AI agents that read from your existing quality data systems without requiring migration or replacement — operates differently. This is the architecture that Qualera has built with their Qualera platform, and it's the technology partner we recommend to clients who need to begin generating quality intelligence now, not in year three.

Qualera reads from existing QMS, ERP, CAPA, and complaint systems. It doesn't require a platform migration. It surfaces risk patterns from the data already living in your organization. The data flywheel begins generating value from the first audit cycle — not after the digital transformation is complete.

For MB&A clients, this means the quality intelligence conversation doesn't have to wait for the infrastructure conversation to conclude. They can run in parallel. Often, they should.

What Regulators Are Already Expecting

We want to be direct about something the survey data doesn't address: regulatory bodies — FDA, notified bodies under EU MDR, and international counterparts — are not slowing their inspection cadence while the life sciences industry works through its connectivity crisis.

FDA 483 observations related to CAPA effectiveness, complaint handling, and corrective action timeliness continue to be among the most frequently cited findings across medical device inspections. The organizations that appear before a regulator with board-defensible evidence — structured, traceable, pattern-identified across their quality data — are in a materially different position than those presenting manually compiled reports from disconnected systems.

Audit intelligence doesn't just accelerate digital transformation. In a regulated environment, it changes the quality of evidence available when it matters most.

Five Things Quality Leaders Should Prioritize Now

1. Don't conflate your infrastructure timeline with your intelligence timeline. A three-to-five-year platform migration plan doesn't have to mean three to five years without audit intelligence. Evaluate the two separately.

2. Map your existing quality data assets before your next transformation decision. Your QMS, CAPA, complaint, and vigilance data is almost certainly more actionable than you're currently extracting from it. Before investing in platform replacement, understand what intelligence you can generate from what you have.

3. Bring regulatory readiness into your AI deployment conversation. If you're evaluating audit intelligence technology, the relevant question isn't "will this integrate with our future architecture?" — it's "can this give my quality team board-defensible evidence before the next inspection?"

4. Address cultural resistance directly, not just technically. The survey data shows nearly 50% of respondents cite cultural resistance as a significant barrier. In our experience, the resistance often comes from quality professionals who are skeptical that AI understands the regulatory nuance of their domain. Purpose-built audit intelligence — built specifically for life sciences quality, not adapted from general-purpose AI — addresses that skepticism with demonstrated capability rather than theoretical claims.

5. Start the data flywheel before your infrastructure is complete. Purpose-built AI agents improve with every audit cycle they process. The quality organizations deploying audit intelligence today will have a compounding data advantage over those waiting for perfect infrastructure — and that advantage accrues in both capability and regulatory preparedness.

MB&A's Perspective

The life sciences industry's instinct for caution serves an important purpose. We counsel clients on regulatory risk for a living — we understand why quality leaders want certainty before they deploy new technology in their compliance-critical processes.

But caution has become paralysis in the AI conversation. The survey data is unambiguous: the industry expects AI to significantly impact quality operations within one to two years, and zero organizations have reached a fully intelligent quality state. The gap between expectation and reality will close — but it won't close if quality leaders keep waiting for a clean infrastructure that may be years away.

MB&A helps medical device companies deploy audit intelligence without waiting for a complete digital overhaul. Contact us to learn how we combine consulting expertise with Qualera technology to accelerate your quality transformation — and to prepare your organization to face its next inspection with the kind of evidence that changes outcomes.

Source: Survey of 300 life sciences professionals in quality and manufacturing functions (March 2026).s exposed.